Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective StudyShigeo Shimose, Takuji Torimura, Hideki Iwamoto et al.|Cancers|2020Cited by 78
Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse EventsHideki Iwamoto, Takuji Torimura, Shigeo Shimose et al.|Cancers|2020Cited by 68
Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysisShigeo Shimose, Takuji Torimura, Takumi Kawaguchi et al.|Oncology Letters|2020Cited by 64
Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical PracticeHideki Iwamoto, Shigeo Shimose, Yu Noda et al.|Cancers|2021Cited by 59
Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching StudyShigeo Shimose, Takuji Torimura, Hideki Iwamoto et al.|Cancers|2021Cited by 57